Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) just unveiled an update.
Oncopeptides AB reported higher-than-expected net sales for Q2 2025, with a 45% increase from Q1 and 135% from Q2 2024, driven by strong organic growth in Germany and rapid market access in Spain and Italy. This marks the third consecutive quarter of over 30% sales growth, positioning the company towards profitability by 2026, reflecting robust demand for its cancer treatment, Pepaxti.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the development and commercialization of targeted therapies for challenging cancer types. Utilizing its proprietary Peptide Drug Conjugate platform, the company delivers cytotoxic agents directly into cancer cells. Oncopeptides’ flagship drug is marketed in Europe, with partnerships extending to South Korea, the Middle East, and Africa. Founded in 2000, the company operates in Sweden, Germany, Austria, Spain, and Italy, and is listed on Nasdaq Stockholm.
Average Trading Volume: 782,963
Current Market Cap: SEK367.6M
Learn more about ONCO stock on TipRanks’ Stock Analysis page.